Search results for " Side Effects"

showing 10 items of 123 documents

Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compounds.

2022

The data currently described was generated within the EU/FP7 HeCaToS project (Hepatic and Cardiac Toxicity Systems modeling). The project aimed to develop an in silico prediction system to contribute to drug safety assessment for humans. For this purpose, multi-omics data of repeated dose toxicity were obtained for 10 hepatotoxic and 10 cardiotoxic compounds. Most data were gained from in vitro experiments in which 3D microtissues (either hepatic or cardiac) were exposed to a therapeutic (physiologically relevant concentrations calculated through PBPK-modeling) or a toxic dosing profile (IC20 after 7 days). Exposures lasted for 14 days and samples were obtained at 7 time points (therapeutic…

Statistics and ProbabilityEpigenomicsProteomicsBioquímicaBiologiaDrug-Related Side Effects and Adverse ReactionsLibrary and Information SciencesCardiotoxicityComputer Science ApplicationsEducationHumansMetabolomicsStatistics Probability and UncertaintyTranscriptomeInformation Systems
researchProduct

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

2012

To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients.Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at -15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between baseline and 72 ± 24 h …

Malemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsContrast MediaNephrogenic Fibrosing DermopathyHeterocyclic CompoundsRisk FactorsOrganometallic CompoundsPrevalenceMedicineHumansRadiology Nuclear Medicine and imagingRenal Insufficiency ChronicneoplasmsNeuroradiologyAgedmedicine.diagnostic_testMegluminebusiness.industryAcute kidney injuryMagnetic resonance imagingInterventional radiologyGeneral MedicineAcute Kidney Injurymedicine.diseaseMagnetic Resonance ImagingEuropeTreatment OutcomeRadiology Nuclear Medicine and imagingNephrogenic systemic fibrosisAngiographyFemaleRadiologybusinessmedicine.drugKidney diseaseEuropean radiology
researchProduct

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Ju…

2017

Abstract Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy. Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The prim…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsPhases of clinical researchIpilimumabDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansAdverse effectAgedbusiness.industryCancerMiddle AgedInterim analysismedicine.diseaseIpilimumabSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleEsophagogastric Junctionbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

When symptoms become side effects: Development of the side effect attribution scale (SEAS)

2021

Objectives\ud \ud Symptom misattribution is a central process in the nocebo effect but it is not accurately assessed in current side effect measures. We have developed a new measure, the Side Effect Attribution Scale (SEAS), which examines the degree to which people believe their symptoms are treatment side effects.\ud \ud \ud \ud Methods\ud \ud The SEAS was tested in three New Zealand studies: a vaccination sample (n = 225), patients with gout or rheumatoid arthritis (n = 102), and patients switching to a generic medicine (n = 69). The internal reliability of the scale was examined using Cronbach's alpha. To assess validity, the Side Effect Attribution Total Score and Side Effect Attributi…

MaleDrug-Related Side Effects and Adverse ReactionsSide effectNocebomedia_common.quotation_subject03 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesHumansMedicineMisattribution of memory030212 general & internal medicinemedia_commonbusiness.industryReproducibility of ResultsNocebo EffectPsychiatry and Mental healthClinical PsychologyScale (social sciences)FemaleWorrybusinessAttribution030217 neurology & neurosurgeryClinical psychologyJournal of Psychosomatic Research
researchProduct

Different effects of biological drugs in rheumatoid arthritis

2013

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity. Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) t…

Cartilage Articularmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsImmunologyArthritisPharmacologyArthritis Rheumatoidchemistry.chemical_compoundChondrocytesPharmacotherapyTocilizumabDrug TherapyRheumatoidInternal medicinemedicineHumansImmunology and AllergyArthritis Rheumatoid; Cartilage Articular; Chondrocytes; Drug Therapy Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation Mediators; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alphaAdverse effectRandomized Controlled Trials as TopicTumor Necrosis Factor-alphabusiness.industryArthritisAbataceptmedicine.diseaseClinical trialCartilagePharmaceutical PreparationschemistryRheumatoid arthritisCombinationDrug Therapy CombinationRituximabInflammation MediatorsbusinessArticularmedicine.drugAutoimmunity Reviews
researchProduct

Digoxin-related leukocytoclastic vasculitis in a very elderly woman: A case report

2016

International audience; Even though digoxin causes many side effects, few cases of skin involvement are recorded in the French Pharmacovigilance Database. We report a case of leukocytoclastic vasculitis (LV) very probably due to digoxin. A 91-year-old woman, hospitalized following a fall, presented cardiac decompensation in a context of rapid atrial fibrillation requiring treatment with digoxin. Eight days later, a rash appeared on her back and trunk. It was neither itchy, nor painful and persisted despite local treatment. There were no other clinical anomalies. After a few days, the rash spread with appearance of bullous lesions, ulcerations and a necrosis on lymphedema of the two legs. Am…

medicine.medical_specialtyDigoxinDigoxinContext (language use)Vascularite leucocytoclasique030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePharmacovigilanceBiopsypolycyclic compoundsmedicinecardiovascular diseasesAdverse side effects030203 arthritis & rheumatologymedicine.diagnostic_testbusiness.industryAtrial fibrillationLeukocytoclastic vasculitismedicine.diseaseEffets indésirablesDermatologyRashLymphedemaSkin biopsyDigoxinemedicine.symptomCardiology and Cardiovascular Medicinebusiness[ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.drug
researchProduct

Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.

2007

The pharmaceutical industry is committed to marketing safer drugs with fewer side effects, predictable pharmacokinetic properties and quantifiable drug-drug interactions. Drug metabolism is a major determinant of drug clearance and interindividual pharmacokinetic differences, and an indirect determinant of the clinical efficacy and toxicity of drugs. Progressive advances in the knowledge of metabolic routes and enzymes responsible for drug biotransformation have contributed to understanding the great metabolic variations existing in human beings. Phenotypic as well genotypic differences in the expression of the enzymes involved in drug metabolism are the main causes of this variability. How…

DrugDiclofenacDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectBiologyPharmacologyIn Vitro TechniquesToxicologyModels BiologicalPharmacokineticsCytochrome P-450 Enzyme SystemIn vivoGenetic variationHumansDrug InteractionsPharmacokineticsBiotransformationCells Culturedmedia_commonMolecular StructureAnti-Inflammatory Agents Non-SteroidalCytochrome P450Genetic VariationGeneral MedicineIn vitroPharmaceutical PreparationsToxicityInactivation Metabolicbiology.proteinHepatocytesDrug metabolismMetabolic Networks and PathwaysChemico-biological interactions
researchProduct

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. Methods Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K arra…

0301 basic medicineOncologymedicine.medical_treatmentADNlcsh:MedicineTriple Negative Breast NeoplasmsEpigenesis Genetic0302 clinical medicineGenetics (clinical)Triple-negative breast cancermedicine.diagnostic_testHigh-Throughput Nucleotide SequencingNuclear ProteinsMethylationMiddle AgedNeoadjuvant TherapyGene Expression Regulation NeoplasticTreatment OutcomeMyogenic Regulatory FactorsEfectes secundaris dels medicaments030220 oncology & carcinogenesisCohortFemaleTaxoidsMetilacióMicrotubule-Associated ProteinsAdultmedicine.medical_specialtylcsh:QH426-470MethylationMinor Histocompatibility Antigens03 medical and health sciencesBreast cancerTriple-negative breast cancerInternal medicineCell Line TumorBiopsyGeneticsmedicineHumansEpigeneticsMolecular BiologyEpigenetic signatureAgedChemotherapybusiness.industryGene Expression ProfilingResearchlcsh:RSequence Analysis DNADNADNA Methylationmedicine.diseaseHuman geneticsRepressor Proteinslcsh:Genetics030104 developmental biologyDrug side effectsbusinessPredictionDevelopmental Biology
researchProduct

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

2021

Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of many cancers as they improve clinical outcomes. However, ICIs have also been associated with the development of immune-related adverse drug reactions (ADRs). Among immune-related ADRs, cardiac immune-related ADRs are rare, but also associated with high mortality rates. Objective The objective of this study was to evaluate the occurrence of cardiac ADRs reported with ICIs in the European spontaneous reporting system. Methods We retrieved individual case safety reports on ICI-induced cardiac ADRs from the website of suspected ADR (www.adrreports.eu) of the European pharmacovigilance database (Eudravigilance).…

medicine.medical_specialtyDurvalumabDrug-Related Side Effects and Adverse ReactionsIpilimumabPembrolizumabToxicology030226 pharmacology & pharmacyPharmacovigilance03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinePharmacovigilancemedicineHumansPharmacology (medical)Original Research Article030212 general & internal medicineMyocardial infarctionImmune Checkpoint InhibitorsPharmacologybusiness.industryOdds ratiomedicine.diseaseIpilimumabNivolumabNivolumabbusinessmedicine.drugDrug Safety
researchProduct

Towards identifying drug side effects from social media using active learning and crowd sourcing.

2019

Motivation Social media is a largely untapped source of information on side effects of drugs. Twitter in particular is widely used to report on everyday events and personal ailments. However, labeling this noisy data is a difficult problem because labeled training data is sparse and automatic labeling is error-prone. Crowd sourcing can help in such a scenario to obtain more reliable labels, but is expensive in comparison because workers have to be paid. To remedy this, semi-supervised active learning may reduce the number of labeled data needed and focus the manual labeling process on important information. Results We extracted data from Twitter using the public API. We subsequently use Ama…

0303 health sciencesFocus (computing)Information retrievalDrug-Related Side Effects and Adverse ReactionsProcess (engineering)business.industryActive learning (machine learning)Computer scienceComputational BiologyCrowdsourcing03 medical and health sciences0302 clinical medicineProblem-based learningCode (cryptography)CrowdsourcingHumansSocial media030212 general & internal medicinebusinessBaseline (configuration management)Social Media030304 developmental biologyPacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
researchProduct